Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

Published:2017-11-07 Issue:17 Volume:318 Page:1679
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Lemaitre Magali¹,Kirchgesner Julien²,Rudnichi Annie¹,Carrat Fabrice³,Zureik Mahmoud¹,Carbonnel Franck⁴,Dray-Spira Rosemary¹

Affiliation:

1. Department of Epidemiology, Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), Saint-Denis, France

2. Department of Epidemiology, Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), Saint-Denis, France2Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, UMR_S 1136, F-75012, Paris, France3Department of Gastroenterology, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France

3. Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, UMR_S 1136, F-75012, Paris, France4Department of Public Health, Hôpital Saint Antoine, AP-HP, F-75012, Paris, France

4. Department of Gastroenterology, Hôpitaux Universitaires Paris Sud, Assistance Publique-Hôpitaux de Paris, Université Paris-Sud, Le Kremlin Bicêtre, France

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 412 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Colon-targeted delivery of niclosamide from solid dispersion employing a pH-dependent polymer via hotmelt extrusion for the treatment of ulcerative colitis in mice;Journal of Drug Targeting;2024-01-05

2. MR Enterography in Ulcerative Colitis: Beyond Endoscopy;RadioGraphics;2024-01-01

3. Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis;Clinical Gastroenterology and Hepatology;2024-01

4. Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases;Clinical Gastroenterology and Hepatology;2024-01

5. Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data;Expert Review of Gastroenterology & Hepatology;2023-12-02